Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States [Yahoo! Finance]
Catalyst Pharmaceuticals, Inc. (CPRX)
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.catalystpharma.com
Company Research
Source: Yahoo! Finance
This follows the first commercial launch of AGAMREE in Germany in January 2024 by Santhera AGAMREE is the first DMD treatment approved across the U.S., EU and UK Pratteln, Switzerland, March 14, 2024 – Santhera Pharmaceuticals (SIX: SANN) is pleased to note the launch of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in the United States (U.S.) by Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), the Company's commercialization partner for North America. “Congratulations to our partner Catalyst on the launch of AGAMREE® in the United States. Following the first global market introduction of this novel product in Germany in January, this launch represents an important next step in making AGAMREE available to as many patients with DMD as soon as possible,” said Dario Eklund, CEO of Santhera The launch of AGAMREE in the U.S. follows the approval of the product by the U.S. Food and Drug Administration (FDA) on October 26, 2023, based on data from the pi
Show less
Read more
Impact Snapshot
Event Time:
CPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPRX alerts
High impacting Catalyst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CPRX
News
- Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024GlobeNewswire
- Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024GlobeNewswire
CPRX
Earnings
- 2/28/24 - Miss
CPRX
Sec Filings
- 4/10/24 - Form 4
- 4/10/24 - Form ARS
- 4/10/24 - Form DEF
- CPRX's page on the SEC website